Axicabtagene-ciloleucel: Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: case report.

A 26-year-old man with refractory diffuse large B-cell lymphoma developed cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment with axicabtagene ciloleucel. He experienced fever and tachycardia consistent with grade 1 CRS, followed by rapidly progressive ICANS characterized by handwriting impairment and encephalopathy. The patient received tocilizumab and dexamethasone, and his ICANS ultimately resolved. MRI scans showed initial abnormalities that later resolved. [Extracted from the article]